BlueSphere Bio Data to be Presented at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
PITTSBURGH, Nov. 03, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today …